{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002690","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.007444+00:00","generated_at":"2026-06-07T02:07:32.610123+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sutro Biopharma reports ~$333M cash, luvelta data in ovarian cancer, AML, NSCLC trials planned","bullets":["Preliminary cash, equivalents, marketable securities ~$333M as of Dec 31, 2023; 0.7M shares of Vaxcyte stock valued ~$42M, funding into 2H2025.","Updated luvelta data in ovarian cancer: improved clinical outcomes and tolerability vs historical chemo; prophylactic G-CSF reduced neutropenia/dose delays.","Luvelta + bevacizumab showed clinical activity regardless of FolRα expression; preclinical NSCLC data showed single-dose activity and benefit with PD-1 blockade.","REFRαME-O1 registration trial in platinum-resistant ovarian cancer enrolling, Part 1 completion expected 1H2024, ~140 sites by end of 2024.","REFRαME-P1 trial initiation in pediatric CBF/GLIS AML planned 1H2024; IND submission in NSCLC planned 1H2024; endometrial cancer development ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002690","json":"https://secwatch.observer/filing/0000950170-24-002690.json","markdown":"https://secwatch.observer/filing/0000950170-24-002690.md","text":"https://secwatch.observer/filing/0000950170-24-002690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024002690/0000950170-24-002690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017024002690/stro-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:07:32.610123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}